These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34898140)

  • 1. Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
    Goyal S; Tisdale J; Schmidt M; Kanter J; Jaroscak J; Whitney D; Bitter H; Gregory PD; Parsons G; Foos M; Yeri A; Gioia M; Voytek SB; Miller A; Lynch J; Colvin RA; Bonner M
    N Engl J Med; 2022 Jan; 386(2):138-147. PubMed ID: 34898140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
    Kanter J; Walters MC; Krishnamurti L; Mapara MY; Kwiatkowski JL; Rifkin-Zenenberg S; Aygun B; Kasow KA; Pierciey FJ; Bonner M; Miller A; Zhang X; Lynch J; Kim D; Ribeil JA; Asmal M; Goyal S; Thompson AA; Tisdale JF
    N Engl J Med; 2022 Feb; 386(7):617-628. PubMed ID: 34898139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
    Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF
    Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy in a Patient with Sickle Cell Disease.
    Ribeil JA; Hacein-Bey-Abina S; Payen E; Magnani A; Semeraro M; Magrin E; Caccavelli L; Neven B; Bourget P; El Nemer W; Bartolucci P; Weber L; Puy H; Meritet JF; Grevent D; Beuzard Y; Chrétien S; Lefebvre T; Ross RW; Negre O; Veres G; Sandler L; Soni S; de Montalembert M; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2017 Mar; 376(9):848-855. PubMed ID: 28249145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
    Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
    Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
    Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
    Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
    Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.
    Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G
    Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
    Persons DA
    Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Betibeglogene Autotemcel Gene Therapy for Non-β
    Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
    N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice.
    Wilkinson AC; Dever DP; Baik R; Camarena J; Hsu I; Charlesworth CT; Morita C; Nakauchi H; Porteus MH
    Nat Commun; 2021 Jan; 12(1):686. PubMed ID: 33514718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Under the hood: The molecular biology driving gene therapy for the treatment of sickle cell disease.
    Waldron E; Tanhehco YC
    Transfus Apher Sci; 2022 Oct; 61(5):103566. PubMed ID: 36115765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells.
    Levasseur DN; Ryan TM; Pawlik KM; Townes TM
    Blood; 2003 Dec; 102(13):4312-9. PubMed ID: 12933581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements.
    Morgan RA; Unti MJ; Aleshe B; Brown D; Osborne KS; Koziol C; Ayoub PG; Smith OB; O'Brien R; Tam C; Miyahira E; Ruiz M; Quintos JP; Senadheera S; Hollis RP; Kohn DB
    Mol Ther; 2020 Jan; 28(1):328-340. PubMed ID: 31628051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease.
    Urbinati F; Wherley J; Geiger S; Fernandez BC; Kaufman ML; Cooper A; Romero Z; Marchioni F; Reeves L; Read E; Nowicki B; Grassman E; Viswanathan S; Wang X; Hollis RP; Kohn DB
    Cytotherapy; 2017 Sep; 19(9):1096-1112. PubMed ID: 28733131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
    Dong AC; Rivella S
    Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
    Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
    Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.
    Jones RJ; DeBaun MR
    Blood; 2021 Sep; 138(11):942-947. PubMed ID: 34115136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.